BIFIDO Swings to Operating Loss in Q1 2026, Signs KRW 25.4B Deal for Seoul Office Building Sale

Q1 2026 separate revenue fell 47.1% YoY to KRW 2.49bn (vs KRW 4.70bn); operating loss of KRW 0.53bn (vs profit of KRW 1.49bn).
Separate net loss of KRW 0.32bn (vs net profit of KRW 0.48bn in Q1 2025).
Consolidated revenue fell 49.5% YoY to KRW 2.50bn (vs KRW 4.95bn); operating loss of KRW 0.60bn (vs profit of KRW 1.40bn).
Consolidated net loss of KRW 1.51bn (vs net profit of KRW 0.19bn in Q1 2025).
On April 9, 2026, signed a contract to sell land and building in Daechi-dong, Gangnam-gu, Seoul (held as non-current assets held for sale, book value KRW 24.86bn) for KRW 25.4bn; balance payment due August 14, 2026.
Recognized an equity-method investment loss of KRW 1.06bn on LophiBio stake; ownership diluted from 16.83% to 7.83%.
Outstanding balance of the 2024 embezzlement incident (KRW 8.07bn) fully recovered (recovery rate 100%).
Short-term borrowings at quarter-end KRW 10.0bn (vs KRW 12.0bn at year-end 2025); debt-to-equity ratio 26.60% (vs 32.09%).
R&D expenses KRW 0.45bn (18.01% of revenue); stock option compensation cost KRW 0.003bn.

ADVERTISEMENT (250px+)